US Prevalence
~1M+
Estimated 200–500 per 100,000 US adults affected. Prevalence increasing with improved CT detection. Significantly underdiagnosed.[1]
What Is It
Definition, mechanism, and the clinical reality of severe bronchiectasis at end of life. What the hospice team needs to understand on day one.
BSI Severe Mortality
>50%
5-year mortality for BSI score ≥9. Exceeds many recognized terminal diagnoses yet palliative infrastructure is underdeveloped.[7]
Sex Distribution
~60% ♀
Female predominance in non-CF bronchiectasis. Higher prevalence in older adults; age and sex both influence presentation.[2]
Pseudomonas Impact
2× Mortality
Chronic P. aeruginosa colonization approximately doubles mortality vs. Pseudomonas-free bronchiectasis and accelerates FEV1 decline.[29]
Bronchiectasis is the permanent and abnormal dilation of the bronchi and bronchioles resulting from destructive inflammation of the airway wall. It is the structural consequence of chronic and recurrent infection and inflammation that destroys the elastic and muscular components of the airway — a disease that, once established, cannot be reversed but only managed. The estimated prevalence in the United States is approximately 200–500 per 100,000 adults (650,000 to over 1.6 million total), with prevalence increasing dramatically with age and having risen significantly in recent decades as CT imaging has improved detection.[1][2]
Bronchiectasis is significantly underdiagnosed and profoundly underrecognized as a terminal condition. Clinicians who have not managed severe bronchiectasis may be unfamiliar with the BSI (Bronchiectasis Severity Index) prognostic score, may not recognize the BSI-severe patient as hospice-eligible, and may continue aggressive antibiotic and airway clearance treatment without initiating palliative care conversations. The mortality associated with severe bronchiectasis exceeds that of many recognized terminal diagnoses — yet the palliative care infrastructure for bronchiectasis is substantially less developed than for COPD, IPF, or even cystic fibrosis.[3][93]
The etiology matters at end stage. Post-infectious bronchiectasis (the most common cause — approximately 30–40% of cases) follows childhood pertussis, tuberculosis, or severe pneumonia. Primary ciliary dyskinesia, CVID (common variable immunodeficiency), allergic bronchopulmonary aspergillosis (ABPA), and autoimmune-associated disease (rheumatoid arthritis) each produce distinct patterns. The etiology determines the dominant pathogen, the natural history, and the comfort management priorities. The hospice clinician who understands why this patient has bronchiectasis understands the disease trajectory ahead.[15][16]
🧭 Clinical framing
The hospice clinician who walks into a severe bronchiectasis home walks into the home of a person who has worked harder to keep their lungs working than almost any other patient in this series. The daily airway clearance routine — the vest, the nebulizers, the OPEP devices — has been as central to their life as eating. Every morning starts the same way: position, clear, nebulize, rest. The FEV1 that was 65% five years ago is now 28%. The Pseudomonas that used to respond to piperacillin-tazobactam now only responds to colistin. Three specific clinical skills are required at enrollment: the hemoptysis kit must be assembled before the bleed; the comfort-directed antibiotic decision must be made while the patient can still participate; and the daily airway clearance routine must be renegotiated in terms of comfort benefit versus exhaustion burden.[7][8]
"Bronchiectasis is the disease nobody outside respiratory medicine thinks of as terminal. Your patient has been fighting this for 20 years with a vest and a nebulizer and a sputum cup every morning. They're not just dying — they're exhausted from the years of fighting. Respect what that daily effort has cost them. And get the hemoptysis kit set up before you leave the first visit — because when the bleed comes, you don't get a second chance to prepare."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging systems, and what the hospice clinician must extract from prior records. Most patients arrive with an established diagnosis — this section helps you read it and calculate the BSI.
HRCT — The Diagnostic Standard
GuidelineHigh-resolution CT (HRCT) of the chest is the diagnostic standard for bronchiectasis.[4]
- Signet ring sign: Internal airway lumen exceeds the diameter of the adjacent pulmonary artery — the pathognomonic finding
- Airway wall thickening: Indicates chronic inflammatory change in bronchial walls
- Lack of tapering: Airways fail to taper normally toward the periphery
- Distribution pattern: Bilateral vs. unilateral; number of lobes involved (key BSI component); upper lobe predominance suggests post-TB or ABPA; middle lobe/lingula suggests NTM (Lady Windermere pattern)
- Associated findings: Mucus plugging, air trapping, tree-in-bud pattern (distal infection), ground-glass change, consolidation, fibrosis
- At hospice enrollment: The HRCT documents the extent of bronchiectasis for BSI calculation and prognostic framework
Sputum Microbiology — The Critical History
GuidelineThe chronic colonizing organism is the single most important microbiological datum in bronchiectasis management.[29]
- Pseudomonas status: Chronic infection = ≥3 positive cultures in prior year, ≥3 months apart, when stable. Document MIC data for ciprofloxacin, piperacillin-tazobactam, ceftazidime, meropenem, colistin, tobramycin
- NTM history: MAC and M. abscessus culture results, susceptibility, prior treatment attempts, duration, and response[37]
- Other MDR organisms: Stenotrophomonas, Achromobacter, Burkholderia cepacia complex, MRSA — each carries distinct management implications
- Most recent sputum culture: Within 3 months of enrollment — document organism and sensitivities for the comfort-directed antibiotic plan
BSI — Bronchiectasis Severity Index Calculation
The BSI is the prognostic tool that supports hospice eligibility documentation. Developed and validated by Chalmers et al. (2014) through EMBARC, the BSI stratifies 4-year mortality as: mild (score 0–4) approximately 0–2.8%; moderate (score 5–8) approximately 0.8–4.8%; severe (score ≥9) approximately 7.6–52%.[7][8]
| BSI Component | Points | Source |
|---|---|---|
| Age ≥70 | 6 pts | Demographics; 50–69 = 2 pts; <50 = 0 |
| FEV1 <30% predicted | 3 pts | Most recent PFT; 30–49% = 2; 50–79% = 1; ≥80% = 0 |
| ≥3 hospitalizations/yr | 5 pts | Prior year hospitalization count; 1–2 = 3; 0 = 0 |
| ≥3 exacerbations/yr | 2 pts | Prior year; 0–2 = 0 |
| MRC Dyspnea ≥4 | 3 pts | MRC breathlessness scale; 1–3 = variable |
| Pseudomonas colonization | 3 pts | Chronic infection status from sputum history |
| Other organism colonization | 1 pt | Non-Pseudomonas chronic colonization |
| ≥3 lobes involved | 1 pt | HRCT report; 1–2 lobes = 0 |
📊 FACED Score — Alternative Prognostic Tool
The FACED score (Martínez-García et al. 2014) offers a simpler 5-variable alternative: FEV1 (F), Age (A), Chronic colonization by Pseudomonas (C), Extension on CT (E), and Dyspnea (D). Scores 0–2 mild, 3–4 moderate, 5–7 severe. Both BSI and FACED are validated — BSI provides more granular risk stratification for hospice documentation purposes.[8][9]
Pulmonary Function Tests
PFTs at Hospice Enrollment
- FEV1 <30% predicted on optimal therapy: Primary hospice eligibility criterion — indicates severe airflow limitation beyond effective treatment[10]
- FEV1 trajectory: Rate of decline more prognostically useful than single value — each exacerbation reduces FEV1 by ~2% that does not fully recover
- Obstructive pattern: Reduced FEV1/FVC ratio typical; mixed obstructive-restrictive if fibrotic change present
- Air trapping: Elevated RV/TLC ratio reflects small airway disease and mucus plugging
What to Extract from Records
- HRCT date and lobar involvement: For BSI calculation
- Pseudomonas chronicity: Number and dates of positive cultures
- Antibiotic sensitivity panel: Most recent MIC data
- NTM culture history: MAC/abscessus — treatment attempted?
- Immunodeficiency workup: CVID, IgG subclass deficiencies
- Hospitalization dates: Last 12 months — for BSI and hospice eligibility
💡 For families
Your person's bronchiectasis was diagnosed using a special CT scan of the chest. The scan shows damaged and widened airways that cannot heal on their own. The severity of the disease is measured using a scoring system called the BSI — this score helps the clinical team understand the stage of the disease and plan the best comfort care. Most of the diagnostic workup is already complete at hospice enrollment — our focus now is entirely on comfort.
Causes & Risk Factors
Bronchiectasis pathogenesis and the clinical relevance for end-of-life management. Why understanding the vicious cycle and the dominant pathogen matters for every comfort decision.
The Cole Vicious Cycle. The pathological hallmark of bronchiectasis progression is the vicious cycle of impaired mucociliary clearance → bacterial colonization → neutrophilic airway inflammation → structural damage → further impaired clearance. The initial event — infection, obstruction, or congenital abnormality — disrupts the mucociliary escalator. Stagnant mucus provides substrate for bacterial colonization. The colonizing bacteria trigger the proteolytic and oxidative damage that destroys the airway wall. This damage further impairs mucociliary function, producing more stagnation, more colonization, and more inflammation — an inescapable cycle once established.[11][12]
The Vicious Cycle & Pseudomonas Transition
Grade A- Haemophilus → Pseudomonas transition: This marks a critical disease progression event. Pseudomonas-colonized bronchiectasis has ~2× mortality, highest exacerbation frequency, most rapid FEV1 decline, and most challenging antibiotic management[29][30]
- MDR Pseudomonas at end stage: Intrinsic resistance via AmpC β-lactamase, MexAB-OprM efflux pump; acquired resistance via OprD loss (carbapenem resistance), additional efflux upregulation, biofilm formation in bronchiectatic airways[32]
- Biofilm formation: Pseudomonas biofilms in the bronchiectatic airway are essentially immune to systemic antibiotics — only inhaled antibiotics achieve local concentrations above the MIC within the biofilm matrix
- Terminal phase organism: MDR Pseudomonas with resistance to all conventional agents represents the endpoint — chronic infection with no eradication option and only the most toxic suppression strategies (IV colistin, IV polymyxin B)
NTM & Other MDR Organisms
Grade B- NTM co-infection: MAC (Mycobacterium avium complex) is the most common NTM in bronchiectasis; M. abscessus is the most treatment-resistant. NTM prevalence in bronchiectasis: 5–15% depending on geography[37][38]
- M. abscessus: Treatment requires prolonged multi-drug regimens (12–18 months); cure rates below 50%; in end-stage bronchiectasis, M. abscessus treatment is rarely comfort-compatible
- Macrolide resistance from monotherapy: Azithromycin monotherapy in NTM-colonized bronchiectasis generates macrolide resistance — eliminates the most effective MAC treatment agent[42]
- Achromobacter, Stenotrophomonas, Burkholderia: Each carries distinct antibiotic profiles and mortality implications — document at enrollment
Etiology Distribution
- Post-infectious (~30–40%): Childhood pertussis, TB, severe pneumonia — structural scar leads to bronchiectasis[15]
- Idiopathic (~25–40%): No identifiable cause despite full workup
- CVID / immunodeficiency (~5–10%): Recurrent infections from antibody deficiency[101]
- ABPA (~2–7%): Allergic bronchopulmonary aspergillosis
- Primary ciliary dyskinesia: Congenital motile cilia dysfunction[18]
- Autoimmune (RA, Sjögren): Airway involvement in systemic disease[19]
Why Etiology Matters at Hospice
- CVID: Immunoglobulin replacement (IVIG/SCIG) may continue as comfort-directed therapy to reduce exacerbation frequency — a specific comfort-benefit discussion[102]
- Post-infectious: Distribution pattern determines which lobes are producing the most secretions — guides positioning for postural drainage
- PCD: Bilateral disease, situs inversus in ~50% — affects physical examination and imaging interpretation
- ABPA: Corticosteroid history — assess for adrenal suppression; antifungal therapy decisions at end stage
❤️ For families: "Why did this happen?"
Bronchiectasis is caused by damage to the airways from infections, immune system problems, or sometimes causes that cannot be identified. This is not something your loved one did wrong. The damage happened to the lungs — often decades ago — and has been progressing despite years of dedicated daily treatment. Your person has fought this disease harder and longer than most clinicians realize.
⚕ Clinician note: Immunodeficiency assessment
Even at hospice enrollment, confirming the etiology matters. If CVID is suspected but undiagnosed, a serum immunoglobulin level can clarify whether immunoglobulin replacement is indicated as a comfort measure to reduce exacerbation frequency. This single lab can change the comfort management strategy.[101]
Treatments & Procedures
Comprehensive clinical framework for severe bronchiectasis end-stage symptom management: airway clearance renegotiation, comfort-directed antibiotics, hemoptysis management, and inhaled therapy reassessment.
Airway clearance is the cornerstone of bronchiectasis self-management that requires explicit renegotiation at hospice enrollment. The question is not whether airway clearance should continue (it should, for comfort) but how much effort, at what frequency, and using which techniques is proportionate to the comfort benefit at end stage. The patient who has been doing twice-daily vest sessions for 20 years deserves a conversation about what that routine means to them and what it costs them now.[45][46]
Airway Clearance — Comfort-Directed Options
OPEP Devices (Aerobika, Acapella, Flutter)
Grade BOscillatory positive expiratory pressure — variable frequency/resistance settings
Provides airway clearance and airway opening through oscillatory positive pressure. Well-tolerated and relatively low effort. Appropriate for most end-stage patients. Frequency reduction from twice-daily to once-daily or as-needed is a reasonable comfort-directed modification.[47]
HFCWO Vest (The Vest System)
Grade BHigh-frequency chest wall oscillation — 20–30 min sessions at prescribed frequency/pressure
Very effective for copious secretion clearance. The vest session requires 20–30 minutes of relatively passive sitting. Time and setup burden is the primary cost. Reduction from twice-daily to once-daily to as-needed is a comfort-directed modification that reduces burden without eliminating benefit.[48]
Active Cycle of Breathing (ACBT)
Grade BBreathing control → thoracic expansion → forced expiration technique (huff coughing)
Entirely non-device; can be performed in any position. The lowest-burden airway clearance technique. Appropriate as the primary technique as device use becomes too burdensome. Teach families the huff cough assistance technique.[49]
Postural Drainage
Grade CPositioning to use gravity for lobe-specific drainage — 10–20 min per position
Tilting and positioning to assist drainage from specific lobes. Increasingly difficult as functional decline progresses. Can be simplified to the positions that provide the most relief — typically draining the most affected lobes identified on HRCT.[50]
Comfort-Directed Antibiotics
The comfort-directed antibiotic decision must be documented at enrollment with explicit distinction from eradication intent. At end stage, antibiotics are comfort medications — they reduce symptom burden from purulent secretions, reduce fever, reduce dyspnea from acute infection, and improve quality of life during exacerbations. They are not being given to cure the infection or eradicate the organism. This distinction must be explicitly documented and communicated to the patient and family.[71][72]
Oral Antibiotic Strategy
- Ciprofloxacin 750 mg BID × 14 days: First-line oral anti-pseudomonal if isolate remains sensitive (check MIC). Comfort indication: purulent exacerbation with increased dyspnea[73]
- Amoxicillin-clavulanate 875/125 mg BID: For Haemophilus-predominant exacerbations; ineffective against Pseudomonas
- Doxycycline 100 mg BID: Alternative for non-Pseudomonal exacerbations; well-tolerated
- Self-start plan: Standing antibiotic prescription at home that patient/family initiates at first signs of exacerbation — reduces delay to treatment[74]
IV / Inhaled Antibiotic Decisions
- IV antibiotics at hospice: When oral options exhausted and symptom burden from exacerbation severe — comfort-directed IV antibiotics (typically 10–14 day course) reduce suffering
- Inhaled colistin/tobramycin: Continue if reducing exacerbation frequency and sputum volume with acceptable nebulization burden (~30–45 min TID); reassess if burden exceeds benefit[33][34]
- Comfort-benefit threshold: If inhaled antibiotic adds 90+ minutes daily nebulization without measurable exacerbation reduction, consider withdrawal
Hemoptysis Management
🩸 Massive Hemoptysis — Pre-Position Before the Bleed
Massive hemoptysis (>300 mL in 24h or >100 mL per episode) carries 5–25% acute mortality without bronchial artery embolization (BAE). The hemoptysis kit must be assembled at the first visit before leaving the home. Dark towels positioned at bedside. Midazolam 10 mg drawn, labeled, and accessible. Morphine drawn and labeled. Tranexamic acid nebulizer solution available. Family prepared for the hemoptysis possibility. Advance directive about emergency transport for BAE documented.[57][58]
- Mild-moderate hemoptysis (blood-streaked sputum to ~50 mL): Nebulized tranexamic acid 500 mg; sit upright; call hospice nurse same day[59]
- Large-volume hemoptysis: Dark towels; immediate midazolam for distress; morphine for dyspnea; call hospice nurse; follow advance directive for hospital transport
- Bronchial artery embolization (BAE): Definitive hemostasis procedure — 85–90% initial success rate; requires IR suite access; advance directive must address transport decision before bleed occurs[58]
Mucolytic & Inhaled Therapy
Hypertonic Saline Nebulization
Grade A7% hypertonic saline 4 mL nebulized BID — pre-treat with bronchodilator
⚠ Dornase Alfa — CONTRAINDICATED
Grade ADO NOT USE in non-CF bronchiectasis
Dornase alfa (DNase/Pulmozyme) is approved for CF but CONTRAINDICATED in non-CF bronchiectasis. The O'Donnell 1998 NEJM trial documented worsening FEV1 and increased exacerbations. Prescribing dornase alfa in non-CF bronchiectasis is a medication error. Check the medication list at enrollment.[55]
When Therapy Makes Sense
Evidence-based criteria for continuing comfort-directed therapies in severe bronchiectasis. The treatments that reduce suffering — not the ones that prolong it.
Comfort-directed therapy in severe bronchiectasis is not about choosing between treatment and hospice. It is about deploying the right treatments — the ones that reduce suffering, prevent predictable crises, and maintain dignity — while withdrawing the ones that add burden without benefit. The following interventions should be initiated or confirmed at enrollment.[93]
- 01BSI score calculated and documented at enrollment: The BSI is the prognostic foundation for all clinical discussions. A BSI of 14 (severe) with a 5-year mortality exceeding 50% and 3 hospitalizations in the prior year provides the documentable prognosis for hospice certification. Calculate it from available data — FEV1, hospitalizations, exacerbation frequency, MRC dyspnea, Pseudomonas status, lobar involvement.[7]
- 02Massive hemoptysis pre-positioned comfort kit at enrollment: Dark towels, midazolam 10 mg drawn and labeled, morphine drawn and labeled, tranexamic acid nebulizer solution available. Family prepared for the hemoptysis possibility before it occurs. Advance directive about emergency transport for BAE documented. This must be complete before leaving the first visit.[57]
- 03Comfort-directed antibiotic decision documented at enrollment: What is the current MDR organism? What antibiotic options remain? What is the symptom-reduction benefit? What is the administration burden? Document the comfort-directed antibiotic strategy with explicit distinction from eradication intent.[71]
- 04Azithromycin anti-inflammatory therapy initiated or confirmed: For any non-CF bronchiectasis patient without NTM colonization and without QTc-prolonging contraindication — the macrolide that reduces exacerbation frequency by 40–70% is the highest-yield comfort medication in bronchiectasis. Grade A evidence from BLESS, BAT, and EMBRACE trials.[61][62][63]
- 05Airway clearance renegotiated at enrollment: The comfort-directed modification of the daily practice — reducing from twice-daily to once-daily, transitioning from vest to OPEP to ACBT as energy declines. The conversation that preserves the patient's sense of agency while reducing exhaustion.[45]
- 06Low-dose morphine for dyspnea at enrollment: The same first-visit dyspnea management imperative as COPD, IPF, and CF. Morphine 2.5–5 mg PO/SQ q4h for breathlessness should be prescribed at the first visit without waiting for respiratory crisis. Evidence: Abernethy 2003 Lancet.[79]
- 07Fan therapy and supplemental oxygen: Fan directed at face reduces dyspnea perception (Galbraith 2010). Supplemental O2 for documented hypoxemia and subjective dyspnea improvement.[81]
- 08Hypertonic saline nebulization continued: As comfort mucolytic — reduces sputum viscosity and the effort of clearance. Well-tolerated and evidence-based.[53]
- 09Inhaled antibiotic comfort-benefit reassessed: If the 3-times-daily nebulized colistin or tobramycin is reducing exacerbation frequency and is tolerable, continue. If it adds 90+ minutes of daily treatment without measurable benefit, discuss withdrawal.[33]
- 10IVIG continuation decision for CVID patients: Immunoglobulin replacement in CVID reduces exacerbation frequency — comfort-benefit analysis at enrollment. SCIG may be preferred over IVIG for lower administration burden.[102]
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in bronchiectasis — a disease that has demanded daily effort for decades.
Bronchiectasis is profoundly under-referred to palliative care. Unlike COPD and IPF, there is no established palliative care pathway for bronchiectasis. The pulmonologist may have managed the patient for 15 years without a palliative care conversation. The hospice referral may arrive years later than it should have — or may only occur after a catastrophic exacerbation. The hospice team must recognize the specific treatments that have crossed from beneficial to burdensome.[93][94]
- 01Dornase alfa (DNase) in non-CF bronchiectasis — the most specific contraindication: DNase is approved for CF and improves outcomes in CF. In non-CF bronchiectasis, the O'Donnell 1998 NEJM trial documented worsening FEV1 and increased exacerbations. Prescribing dornase alfa in non-CF bronchiectasis is a medication error. Document this contraindication prominently in the care plan. If it is on the medication list — stop it at the first visit.[55]
- 02Azithromycin before NTM status is assessed: Azithromycin monotherapy in a patient with active NTM colonization or infection produces macrolide resistance that eliminates the most effective agent in MAC treatment. Before starting azithromycin for anti-inflammatory maintenance, confirm the last NTM sputum culture result (ideally within 12 months). If NTM is present, azithromycin cannot be used as monotherapy.[42]
- 03QTc-prolonging drug combination with azithromycin: Azithromycin QTc prolongation requires ECG before initiation. Concurrent QTc-prolonging agents — fluoroquinolones (ciprofloxacin, levofloxacin), haloperidol, amiodarone, antipsychotics — require specific assessment. New arrhythmia on azithromycin requires evaluation.[67]
- 04Aggressive airway clearance at end of life when exhaustion exceeds benefit: The twice-daily vest taking 2 hours of a patient's day and exhausting them without meaningful secretion benefit should be reduced or modified. The comfort-directed airway clearance conversation that has not happened by the second visit has allowed unnecessary treatment burden to continue.[96]
- 05Inhaled antibiotic without measurable benefit: The inhaled antibiotic adding 45 minutes of nebulization time daily without reducing exacerbation frequency meaningfully — reassess and consider withdrawal. The colistin producing nephrotoxicity above the comfort-acceptable threshold — reassess.[33]
- 06Bronchoscopy and BAL for diagnostic purposes: In an end-stage bronchiectasis hospice patient, diagnostic bronchoscopy is almost never indicated. The microbiology is established. The risk of the procedure exceeds the comfort benefit of additional diagnostic information. Exception: therapeutic bronchoscopy for mucus plug causing lobar collapse with severe dyspnea.
- 07NTM eradication treatment at hospice stage: Multi-drug NTM treatment regimens (12–18 months, multiple daily medications, IV amikacin) are not comfort-compatible in most hospice patients. The exception is when active NTM is the primary driver of symptomatic decline and the patient explicitly chooses treatment — document the comfort-directed rationale.[38]
- 08IV aminoglycoside courses in the setting of established ototoxicity: The patient who has already lost significant hearing from cumulative tobramycin/amikacin exposure should not receive additional aminoglycoside courses unless there is no alternative and the patient is fully informed of the additional hearing risk.[89]
📋 Clinician note: The treatment burden conversation
The bronchiectasis patient at hospice stage has been following a treatment regimen that may consume 3–4 hours daily (vest + nebulized antibiotics + nebulized saline + chest physiotherapy). The total daily treatment burden must be assessed at enrollment and renegotiated with the patient. Ask: "Walk me through your typical morning. How long does your routine take? Which parts feel like they help, and which parts feel like they just take your time and energy?" The answer tells you what to keep and what to let go.[100]
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches specific to severe bronchiectasis. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical; D = expert opinion.
Long-Term Azithromycin Anti-Inflammatory Therapy
Grade AAzithromycin 250–500 mg PO three times weekly (Mon/Wed/Fri) — continuous
The most evidence-supported, most impactful, and most underutilized comfort medication in non-CF bronchiectasis. Three landmark RCTs (BLESS, BAT, EMBRACE) independently demonstrated 40–70% reduction in exacerbation frequency. Mechanism: macrolide anti-inflammatory effect via NF-κB pathway inhibition, neutrophil migration reduction, and bacterial virulence factor suppression — independent of direct antimicrobial action.[61][62][63]
- Prerequisites: Exclude NTM colonization (sputum culture within 12 months); baseline ECG for QTc; assess concurrent QTc-prolonging medications
- Monitoring: QTc reassessment if symptoms suggest arrhythmia; audiometric awareness for ototoxicity with long-term use[68]
- Comfort impact: Fewer exacerbations = fewer antibiotic courses = less hospitalization risk = more stable comfort
Nebulized Tranexamic Acid for Hemoptysis
Grade BTranexamic acid 500 mg (5 mL of 100 mg/mL) in 5 mL NS — nebulized over 20–30 min
Topical antifibrinolytic delivered directly to the airway surface where bleeding is occurring. Multiple case series and small clinical trials in bronchiectasis, lung cancer, and TB-related hemoptysis demonstrate reduction in hemoptysis severity and duration.[59][60]
- Protocol: At first sign of any hemoptysis, nebulize TXA; repeat q4–8h during active hemoptysis
- Pre-position: TXA ampules with nebulization protocol at bedside alongside dark towels and midazolam
- Limitation: Comfort reduction of anticipated symptom, not definitive hemostasis — BAE advance directive must still be in place
Pulmonary Rehabilitation — Adapted for End Stage
Grade AAdapted exercise program: gentle upper/lower extremity exercises, breathing retraining, 10–20 min sessions
Pulmonary rehabilitation improves exercise capacity, quality of life, and dyspnea in bronchiectasis (multiple RCTs). At hospice stage, a modified rehabilitation program — adapted to current functional capacity — maintains functional independence longer and reduces the deconditioning that accelerates decline.[83]
- Adaptation: Chair-based exercises, gentle stretching, pursed-lip breathing practice, energy conservation education
- Who benefits most: Patients who were active before enrollment and for whom inactivity causes psychological distress
Oral Tranexamic Acid for Recurrent Hemoptysis
Grade CTranexamic acid 1 g PO TID for 5–7 days during hemoptysis episodes
Oral tranexamic acid provides systemic antifibrinolytic support for recurrent non-massive hemoptysis. Limited but positive evidence in bronchiectasis. Can be used alongside nebulized TXA for layered antifibrinolytic approach.[61]
- Caution: Thromboembolic risk in immobile patients — assess DVT risk before starting
- Duration: Short courses (5–7 days) during active hemoptysis; not for continuous prophylaxis
Low-Dose Chest CT Surveillance — Discontinuation Decision
Grade DExpert consensus: discontinue routine surveillance imaging at hospice enrollment
Routine CT surveillance adds radiation, transport burden, and anxiety without changing comfort management in most hospice patients. Exception: CT for acute clinical change (suspected mucus plug causing lobar collapse, new consolidation suggesting abscess) where the result would change comfort-directed management.
Singing for Lung Health
Grade CStructured singing exercises — 20–30 min sessions, 2–3 times weekly
Emerging evidence that structured singing programs improve respiratory muscle function, quality of life, and psychological well-being in chronic respiratory disease. Small studies in bronchiectasis and COPD. Provides an enjoyable alternative to formal breathing exercises and has documented psychosocial benefits.[97]
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to severe bronchiectasis. Patients will use supplements — this section helps you have the right conversation.
⚠ Supplement Safety in Severe Bronchiectasis
Four simultaneous safety concerns define the supplement landscape: (1) QTc-prolonging interactions — azithromycin and fluoroquinolones both prolong QTc; supplements with QTc-prolonging properties (high-dose licorice root, high-dose zinc >150 mg) add risk; (2) MDR organism management — herbal preparations with antibacterial properties may have unpredictable effects on the carefully balanced chronic infection; (3) Cumulative nephrotoxicity — years of aminoglycosides may have caused CKD; renally-cleared supplements accumulate; assess eGFR; (4) Mucolytic interactions — supplements with mucolytic properties interact with hypertonic saline and airway clearance strategy.
"Bronchiectasis patients are often the most medically literate patients you will ever meet. They have been managing a complex disease for decades. When they ask about supplements, they are not asking naively — they have usually already researched it. Meet them where they are. Tell them what is specific to bronchiectasis rather than giving them general respiratory supplement advice."
— Waldo, NP
| Supplement | Evidence | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| N-Acetylcysteine (NAC) | Grade B | 600 mg PO TID | Anti-inflammatory via glutathione replenishment; direct mucolytic via disulfide bond reduction in mucin. Reduces airway oxidative stress. Multiple studies show reduced exacerbation frequency in chronic airway disease.[56] | Well-tolerated. GI upset at high doses. May potentiate mucolytic effect of hypertonic saline — additive benefit possible. Monitor for over-hydration of airway secretions in patients with already copious thin secretions. |
| Honey (Manuka) | Grade C | 10–20 mL daily (food-grade Manuka UMF 10+) | In vitro antibacterial activity against P. aeruginosa and MRSA biofilms. Antioxidant properties. Demulcent effect on irritated airways. May reduce cough severity. | Safe in most patients. Caloric content consideration in patients with poor appetite. Not a substitute for antibiotics. Avoid in patients with severe diabetes unless carb-counted. |
| Vitamin D3 | Grade B | 2000–4000 IU daily | Vitamin D deficiency is prevalent in bronchiectasis (50–70% of patients). Supplementation associated with reduced exacerbation frequency in deficient patients. Immune modulation benefit. Check 25-OH-D level at enrollment.[98] | Safe at recommended doses. Caution above 4000 IU daily without monitoring. Hypercalcemia risk in patients with granulomatous disease. Assess kidney function (CKD from prior aminoglycosides). |
| Quercetin | Grade C | 500 mg PO BID | Flavonoid with anti-inflammatory, antioxidant properties. In vitro inhibition of neutrophil elastase relevant to bronchiectasis airway damage. Limited clinical data specifically in bronchiectasis. | Generally well-tolerated. May interact with CYP3A4-metabolized drugs. Theoretical interaction with fluoroquinolones — limited clinical significance. Monitor if concurrent multiple supplements. |
| Pelargonium sidoides (Umckaloabo) | Grade C | 30 drops TID or 20 mg TID (standardized extract) | Demonstrated benefit in acute bronchitis (multiple RCTs). Antimicrobial and immune-stimulating properties. May reduce severity of acute exacerbations. | Generally safe. Potential anticoagulant interaction — caution if hemoptysis history. Liver toxicity case reports (rare). Discontinue if hemoptysis worsens. |
| Omega-3 Fatty Acids | Grade C | EPA/DHA 2–3 g daily | Anti-inflammatory effect via resolution pathway. Evidence in COPD and asthma for reducing airway inflammation. Limited direct bronchiectasis data. | Mild GI effects. Theoretical antiplatelet effect at high doses — assess hemoptysis risk. Fish oil may prolong bleeding time — important in patients with hemoptysis history. |
| Zinc | Grade C | 15–30 mg daily (elemental) | Immune function support. Zinc deficiency common in chronic infection. May reduce infection severity. | ⚠ High-dose zinc (>150 mg) may prolong QTc — critical with azithromycin or fluoroquinolone regimen. Keep below 40 mg/day. Copper depletion with chronic use >50 mg. |
| Probiotics | Grade C | Multi-strain, 10+ billion CFU daily | Gut microbiome support during chronic antibiotic use. May reduce antibiotic-associated diarrhea. Emerging evidence for gut-lung axis immune modulation. | Safe in most patients. Avoid in severely immunocompromised (CVID with very low IgG). Separate from antibiotics by 2 hours. Theoretical concern in patients with central lines. |
🚫 Avoid in Severe Bronchiectasis
- Licorice root (Glycyrrhiza glabra): QTc prolongation risk compounds with azithromycin and fluoroquinolones. Hypokalemia risk further increases arrhythmia vulnerability. Contraindicated in patients on macrolide or fluoroquinolone maintenance.
- Garlic supplements (high-dose allicin): Antiplatelet and antithrombotic effects increase hemoptysis risk in patients with bronchial artery erosion. Food-level garlic is acceptable; concentrated supplements are not.
- Ginkgo biloba: Antiplatelet effect increases bleeding risk — contraindicated in patients with hemoptysis history or active bronchial artery vulnerability.
- Echinacea (long-term use): Immunostimulation may be counterproductive in the complex immune-infection balance of colonized bronchiectasis. Short courses for acute viral illness may be acceptable; chronic use is not recommended.
- St. John's Wort: CYP3A4 induction reduces fluoroquinolone levels, potentially reducing antibiotic efficacy during exacerbations. Also reduces azithromycin levels.
Timeline Guide
A guide, not a prediction. The bronchiectasis trajectory spans decades — from a childhood infection to hospice enrollment. Every patient's path is shaped by etiology, dominant pathogen, exacerbation frequency, and treatment response.
Bronchiectasis is uniquely defined by its multi-decade timeline. The patient at hospice enrollment has typically been living with this disease for 10–30+ years. The progression follows a pattern of exacerbation and partial recovery, with each cycle leaving the lungs slightly worse than before. Understanding where the patient is in this trajectory — and what events brought them to hospice — is essential for every clinical conversation.[3][10]
YRS–
DECS
DECS
Phase 1: The Incident — Initiating Event & Diagnosis
- The childhood pertussis that destroyed the right middle lobe; the TB that was treated but left structural scars; the first unusual pneumonia in the 30s that was never fully explained[15]
- The immunodeficiency discovered when the third pneumonia in 18 months triggered an immunological workup; the CVID diagnosis that explained decades of infection
- The first CT scan showing bronchiectasis — the moment the damage became visible and named
- The pulmonologist who started the daily airway clearance routine — the beginning of a treatment regimen that will continue for decades
- FEV1 at diagnosis often 60–80% predicted; disease perceived as manageable; prognosis not yet discussed
YRS–
DECS
DECS
Phase 2: Management Years — Daily Treatment & Intermittent Exacerbations
- The vest acquired at age 38 and used every morning since; the nebulizers that became the background soundtrack of daily life[45]
- The first positive Pseudomonas sputum culture at age 45 — the colonization event that marks the beginning of a different disease[29]
- Inhaled colistin started when Pseudomonas colonization became chronic; azithromycin started when exacerbations became more frequent[61]
- FEV1 declining from 65% at age 50 to 40% at age 60 — a trajectory measured in decades, not months
- The first moderate hemoptysis event that terrified the patient and family and resolved spontaneously
- Hospitalizations beginning: first at 56, second at 59, third at 61 — frequency increasing
MOS–
YRS
YRS
Phase 3: Escalating Exacerbations — Approaching Hospice Threshold
- IV antibiotic courses becoming more frequent — 3 or more per year; MDR Pseudomonas now only responds to IV colistin[32]
- FEV1 dropped from 40% to 28% in 3 years; each exacerbation takes more and leaves less
- BSI score calculated at 14 (severe) — 5-year mortality exceeding 50%; the pulmonologist finally says the words that have been in the room for two years[7]
- Continuous supplemental oxygen initiated; pulmonary hypertension developing from chronic hypoxemia[85]
- The palliative care conversation that should happen at this stage — and in most cases does not happen until much later[93]
- Weight loss, increasing fatigue, functional decline — activities of daily living becoming difficult
WKS–
MOS
MOS
Phase 4: Hospice Enrollment — Comfort-Directed Care
- Hospice enrollment criteria met: FEV1 <30% predicted on optimal therapy; continuous O2; ≥3 severe exacerbations/yr requiring hospitalization; MDR organism without effective antibiotic options; or patient choice for comfort
- First visit priorities: hemoptysis kit assembled, BSI documented, comfort-directed antibiotic plan written, airway clearance renegotiated, morphine for dyspnea prescribed[79]
- Azithromycin initiated or confirmed (after NTM exclusion and QTc assessment) — the comfort medication that reduces exacerbation frequency by 40–70%[62]
- Treatment burden renegotiation: from curative-intent clearance to comfort-directed clearance; frequency reduction; technique simplification
- Family education: hemoptysis emergency protocol, exacerbation self-start antibiotic plan, when to call hospice nurse
- Psychosocial assessment: 20 years of daily treatment effort acknowledged; treatment fatigue named; identity beyond the vest explored
HRS–
DAYS
DAYS
Phase 5: Final Hours — Active Dying
- Secretions may increase significantly — suctioning may be needed for comfort, but aggressive suctioning can cause more distress; glycopyrrolate 0.2 mg SQ q4h for secretion management[79]
- Dyspnea management: morphine titrated to comfort; midazolam available for refractory respiratory distress; fan continues; O2 continues if it provides comfort
- Hemoptysis risk persists until death — the hemoptysis kit remains accessible; family knows the protocol
- Airway clearance discontinued when patient no longer tolerates any intervention — positioning for comfort only
- Cheyne-Stokes or agonal breathing patterns emerge; noisy breathing from terminal secretions — family education: "This sound is not distressing to your person"
- Presence, touch, familiar voices — the treatment has changed but the care has not
- Emergency medications drawn and labeled: midazolam for catastrophic hemoptysis or terminal agitation; morphine for dyspnea crisis
Medications to Anticipate
Symptom-targeted pharmacology for severe bronchiectasis at hospice. Three non-negotiable safety acts at enrollment. Complete comfort kit. Decision tree for symptom management.
🚨 Three Non-Negotiable Safety Acts at Enrollment
- 1. DORNASE ALFA (DNASE) CONTRAINDICATED IN NON-CF BRONCHIECTASIS — If the patient is prescribed dornase alfa and does not have CF, this is a prescribing error. O'Donnell 1998 NEJM demonstrated worse outcomes. Correct at enrollment. Document prominently.[55]
- 2. AZITHROMYCIN QTc ASSESSMENT BEFORE INITIATION — Obtain baseline ECG. Assess concurrent QTc-prolonging medications (fluoroquinolones, haloperidol, antihistamines). Document QTc baseline. Do not initiate or continue without this assessment.[67]
- 3. EXCLUDE NTM BEFORE AZITHROMYCIN MONOTHERAPY — Review most recent NTM sputum culture (ideally within 12 months). Azithromycin monotherapy in NTM-colonized bronchiectasis generates macrolide resistance that eliminates the most effective MAC treatment agent.[42]
Beyond these three acts: comfort-directed antibiotic decision must be documented; hemoptysis kit must be assembled before leaving the first visit; airway clearance renegotiation must be initiated at enrollment.
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Azithromycin | Macrolide anti-inflammatory / Exacerbation reduction | 250–500 mg PO 3×/wk | Grade A evidence (BLESS, BAT, EMBRACE). Most impactful comfort medication. Initiate after QTc ECG + NTM culture exclusion. 40–70% exacerbation reduction.[61][62][63] |
| Morphine | Opioid / Dyspnea + Pain | 2.5–5 mg PO/SQ q4h | First-line for dyspnea. Prescribe at first visit. Systemic route only — nebulized opioids lack evidence. Titrate to comfort. Add bowel regimen day one.[79] |
| Ciprofloxacin | Fluoroquinolone / Pseudomonas exacerbation | 750 mg PO BID × 14 days | First-line oral anti-pseudomonal if isolate sensitive. Self-start plan: standing prescription at home. ⚠ QTc prolongation — assess with azithromycin[73] |
| Hypertonic saline | Mucolytic / Secretion clearance | 7% NaCl 4 mL neb BID | Continue as comfort mucolytic. Pre-treat with salbutamol 2 puffs to prevent bronchospasm. Reduces sputum viscosity and clearance effort.[53] |
| Tranexamic acid (nebulized) | Antifibrinolytic / Hemoptysis | 500 mg in 5 mL NS neb q4–8h PRN | Pre-position at bedside. At first sign of hemoptysis, nebulize. Comfort reduction of bleeding — not definitive hemostasis.[59][60] |
| Midazolam | Benzodiazepine / Catastrophic event + terminal agitation | 2.5–5 mg SQ/IM PRN | Pre-drawn and labeled at bedside for massive hemoptysis and terminal agitation. Family trained on administration. Critical component of hemoptysis comfort kit. |
| Inhaled colistin | Inhaled antibiotic / Pseudomonas suppression | 1–2 MU neb BID–TID | Continue if reducing exacerbation frequency with acceptable nebulization burden. Reassess if adding >90 min daily without benefit. ⚠ Nephrotoxicity monitoring[33] |
| Inhaled tobramycin | Inhaled aminoglycoside / Pseudomonas suppression | 300 mg neb BID (28 days on / 28 off) | Alternative to colistin. ⚠ Ototoxicity — assess hearing at enrollment; discontinue if hearing deteriorating[34][89] |
| Lorazepam | Benzodiazepine / Anxiety + Dyspnea anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Adjunctive for anxiety component of dyspnea. Limited evidence for dyspnea alone. Identify triggers: dyspnea, anticipatory grief, existential distress. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | Preferred over hyoscine — no CNS effects. For terminal secretions when repositioning insufficient. Family education: sound worse than patient experience. |
| Salbutamol (albuterol) | Bronchodilator / Bronchospasm pre-treatment | 2 puffs MDI or 2.5 mg neb before hypertonic saline | Pre-treatment before hypertonic saline to prevent bronchospasm. Also PRN for acute bronchospasm. Continue long-acting bronchodilator if already prescribed. |
| Dexamethasone | Corticosteroid / Severe exacerbation adjunct | 4–8 mg PO daily × 5–7 days | Short courses for severe exacerbation with significant airway inflammation. Not for maintenance. Monitor glucose. Role in bronchiectasis less established than COPD — use for specific symptom benefit |
| Mirtazapine | Antidepressant / Depression + insomnia + anorexia | 7.5 mg PO QHS | First-line for depression in hospice — addresses depression, insomnia, and appetite simultaneously. Faster onset than SSRIs. No QTc concern. |
| N-Acetylcysteine (NAC) | Mucolytic-antioxidant / Adjunct | 600 mg PO TID | Anti-inflammatory and mucolytic adjunct. Well-tolerated. Complement to hypertonic saline — different mechanism.[56] |
| IVIG/SCIG | Immunoglobulin / CVID exacerbation reduction | SCIG 100–200 mg/kg/wk or IVIG 400–600 mg/kg q3–4wk | Continue in CVID patients if reducing exacerbation frequency. SCIG preferred for lower administration burden. Comfort-benefit discussion at enrollment.[102] |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adapted · Bronchiectasis-specificSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for Severe Bronchiectasis
- Massive Hemoptysis Kit: Dark towels at bedside; Midazolam 10 mg drawn, labeled, accessible; Morphine drawn and labeled; Tranexamic acid 500 mg ampules + nebulizer; Family trained on protocol[57]
- Dyspnea Crisis: Morphine 5–10 mg PO/SQ; Fan at bedside; Lorazepam 1 mg SQ/PO; Midazolam 5 mg SQ for refractory dyspnea
- Exacerbation Self-Start: Standing antibiotic prescription labeled and accessible (ciprofloxacin or per sensitivity); family educated on when to start
- Terminal Secretions: Glycopyrrolate 0.2 mg SQ × 6 doses; gentle suction equipment if copious secretions expected
- Terminal Agitation: Midazolam 5 mg SQ PRN × 4 doses; Haloperidol 1 mg SQ q4–6h × 4 doses
Clinician Pointers
High-yield clinical pearls for the hospice team managing severe bronchiectasis. The things not in the textbook — learned at the bedside over years.
1
Assemble the hemoptysis comfort kit at the first visit — before leaving
The patient's prior moderate hemoptysis event and the MDR Pseudomonas colonization make massive hemoptysis a predictable risk. Before leaving the first visit: place dark towels, draw midazolam and morphine and label them, prepare the tranexamic acid nebulizer solution, sit with the family for 10 minutes to explain the kit and what to do. The hemoptysis that occurs in a home without this preparation is a traumatic death the clinical team could have prevented. The advance directive about emergency transport for BAE must be documented at this visit.[57]
2
Calculate and document the BSI score at enrollment
Use available clinical data: FEV1, prior hospitalization count (12 months), exacerbation frequency, MRC dyspnea score, Pseudomonas status, other colonization, radiological lobar involvement. A BSI of 14 (severe) with a 5-year mortality exceeding 50% provides the documentation the hospice certification requires. It is also the clinical foundation for the prognostic conversation: "The severity score predicts a 5-year mortality above 50% — this is the basis for our hospice enrollment and the conversations we need to have about what you want the remaining time to look like."[7]
3
Confirm dornase alfa is NOT on the medication list
Pull the medication list at the first visit. Look for "Pulmozyme" or "dornase alfa." If it is present and the patient does not have CF, call the prescribing clinician before leaving. The O'Donnell 1998 NEJM trial result — worse FEV1 and more exacerbations with DNase in non-CF bronchiectasis — is one of the clearest negative trial results in pulmonary medicine. The patient on dornase alfa for non-CF bronchiectasis is being actively harmed.[55]
4
Initiate or confirm azithromycin after NTM exclusion and QTc baseline
Obtain ECG before leaving or within 48 hours. Review last NTM sputum culture (within 12 months). If both acceptable, initiate azithromycin 250–500 mg three times weekly. The Grade A evidence for 40–70% exacerbation reduction makes this the highest-yield single addition to the comfort medication regimen. Every day this medication is delayed is a day of preventable exacerbation risk.[61][62][63]
5
Have the airway clearance renegotiation conversation at enrollment
Ask: "Walk me through your morning routine. How long does it take? Which parts feel like they help, and which parts feel like they just take your energy?" Then negotiate comfort-directed modifications: vest from twice-daily to once-daily; transition to OPEP when vest becomes too burdensome; ACBT (huff coughing) as the final technique when all devices are too much. The patient who has been doing this for 20 years deserves a conversation that acknowledges the meaning of that effort.[45][96]
6
Assess hearing at enrollment — aminoglycoside ototoxicity
The patient who has had years of IV tobramycin or amikacin courses may have developed significant hearing loss that has never been formally assessed or acknowledged. Ask directly: "Has your hearing changed over the years of IV antibiotics?" Document the answer. If hearing loss is significant, ensure communication accommodations are in place and avoid further aminoglycoside exposure. Hearing loss from ototoxicity is irreversible and is a quality-of-life determinant that deserves explicit attention.[89][90]
7
Assess for pulmonary hypertension and cor pulmonale
Chronic hypoxemia from bronchiectasis can produce pulmonary hypertension (PH) and right heart failure. Check for peripheral edema, JVD, hepatomegaly, and worsening hypoxemia disproportionate to lung disease. Prior echocardiogram may document elevated RVSP. PH-specific therapy is generally not indicated for PH secondary to lung disease — focus on optimizing oxygenation and managing right heart failure symptoms (diuretics for edema, positioning).[85][86]
8
Equity note: Bronchiectasis disparities
Bronchiectasis prevalence and outcomes show documented disparities. Indigenous populations (Australian Aboriginal, Native Hawaiian, Alaska Native communities) have significantly higher bronchiectasis prevalence. Access to specialist pulmonary care, vest therapy equipment, and inhaled antibiotic access varies by insurance status and geography. The patient without a vest who could benefit from one deserves advocacy for equipment access even at hospice stage. The patient without subspecialty pulmonary care history may have an undiagnosed underlying etiology that changes management.
"The first thing I do in a bronchiectasis home is look at the morning setup — the vest machine, the nebulizer, the sputum cups, the medication bottles. That setup tells you how long this person has been fighting. The second thing I do is check the medication list for dornase alfa. I have found it twice. Both times it was a prescribing error that had been running for months. The third thing I do is set up the hemoptysis kit. Everything else can wait until the second visit."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
The specific psychosocial landscape of severe bronchiectasis: identity built around daily treatment, 20 years of exhaustion, hearing loss grief, and the caregiver who has watched it all.
Psychosocial and spiritual distress in terminal illness is as clinically significant as pain — and in bronchiectasis, it has a specific character shaped by years of daily treatment effort. Depression affects 20–30% of hospice patients and is systematically underdiagnosed. In bronchiectasis, the psychological burden is compounded by the exhaustion of a disease that has demanded daily physical effort for decades.[93][94]
Identity & the Daily Treatment Ritual
Who Am I When the Vest Comes Off?
The bronchiectasis patient who has been doing twice-daily airway clearance for 20 years has organized their morning around a medical ritual as central to daily life as eating. The vest, the nebulizers, the OPEP device — these are not merely treatments. They are the infrastructure of daily survival.
The hospice conversation about reducing treatment burden is also a conversation about giving something up that has been central to the patient's sense of agency over the disease.
The chaplain who acknowledges the meaning: "Tell me about your morning routine — what has it meant to you to have done all of this for 20 years?" opens a conversation about identity, control, and the meaning of effort in the face of an advancing disease.[96]
Treatment Fatigue — The Grief of Exhaustion
The bronchiectasis patient at hospice stage is not only dying from their disease — they are exhausted by years of fighting it. Chronic fatigue from daily airway clearance, recurrent infections, hospitalizations, antibiotic courses, the sound of the vest machine — all accumulated into a specific form of illness-related exhaustion.
The social worker who asks: "When did you last feel like the treatment was worth the effort?" opens the most specific grief conversation in bronchiectasis. The answer often reveals that the patient has been wanting to reduce treatment for months but did not have permission from the clinical team to do so.[99]
Hearing Loss — The Silent Disability
Clinical Pearl — Aminoglycoside Ototoxicity
The patient who has developed significant hearing loss from years of IV tobramycin or amikacin has lost a sensory capacity that they may have grieved privately without clinical acknowledgment. The hearing loss is permanent and progressive. The social worker who asks "How has the hearing change affected your daily life and your relationships?" opens a grief conversation that has often been suppressed for years. Hearing aids should be offered; communication accommodations documented; and the loss explicitly named as a consequence of the treatment that kept them alive longer.[89][90]
Caregiver Burden — The Witness
The Caregiver Who Has Watched for Decades
- Chronic caregiver burden: The spouse who has been the morning treatment partner for 15 years — running the vest, preparing nebulizers, cleaning equipment — carries a cumulative care burden measured in years, not weeks[99]
- Hemoptysis fear: The family member who has witnessed a moderate hemoptysis episode carries specific PTSD-like anticipatory anxiety about a recurrence — this must be named and addressed at enrollment
- Sound of the vest: The rhythmic sound of the HFCWO vest has been the household's morning alarm for years — when it stops, the silence itself becomes a grief trigger
- Caregiver screening: PHQ-2 for the primary caregiver at every visit. Caregiver exhaustion in bronchiectasis is predictable and diagnosable.
Spiritual & Existential Dimensions
- "I did everything right and it still got worse": The patient who followed every treatment protocol for 20 years and is still dying faces a specific existential challenge about the meaning of effort and compliance
- The meaning of the daily fight: Use FICA framework — Faith, Importance, Community, Address. Ask: "What has given you strength to do this daily treatment for all these years?"
- Legacy work: "What do you want people to know about what it was like to live with this disease?" — both assessment and intervention for meaning-making
- Chaplain referral at enrollment: Not at crisis. The spiritual dimension of bronchiectasis is about the meaning of prolonged effort, not just mortality.
Depression Screening & Goals-of-Care Communication
Depression — Screen at Enrollment
Grade B- Single-question screen: "Are you depressed?" — 100% sensitivity in terminally ill populations when phrased directly
- PHQ-2: "Little interest/pleasure" + "Feeling down/hopeless" — score ≥3 warrants full PHQ-9
- Mirtazapine 7.5 mg QHS: First-line in hospice — addresses depression, insomnia, and anorexia simultaneously
- Distinguish depression from appropriate grief about disease progression — both deserve attention; only one warrants pharmacotherapy
Goals-of-Care: Bronchiectasis-Specific
- "What is your understanding of where things stand with your bronchiectasis?" — assesses illness understanding
- "The severity score predicts that more than half of patients with this level of disease do not survive five years. How does that match your own sense of where things are?"
- "If another serious bleed happens, what would you want us to do?" — hemoptysis-specific advance directive
- "The treatment routine you've been doing every day — how much of it still feels worth the effort, and how much of it feels like it's just taking your time?"
"The bronchiectasis patient has been a fighter longer than almost anyone else on your caseload. They have done their treatments every single day for years. And now they are dying despite all of that effort. The existential question is not 'was it worth it' — the question is 'what does it mean that I did everything right and I'm still here?' Sit with that question. Don't rush past it. It is the most important conversation you will have with this patient."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside. Specific to severe bronchiectasis.
Your person has severe bronchiectasis — a lung disease that has damaged the airways and made them wider than normal. This damage makes it hard to clear mucus, which leads to repeated infections. Your person has been managing this disease with daily treatments for years — possibly decades. You have been part of that effort, and your support has mattered enormously. The hospice team is here now to help adjust the daily routine so it focuses on comfort and quality of life rather than aggressive treatment that has become more burdensome than helpful.
What You May See
- Lots of coughing and mucus: This is the most visible symptom of bronchiectasis. The coughing is the body's way of clearing the mucus from the damaged airways. The amount and color of the mucus may change — more mucus or darker/greener mucus can be a sign of a new infection.
- Shortness of breath: Your person may become more breathless over time, especially with activity. A fan blowing toward the face can help with the feeling of breathlessness — this has been proven in research.
- Blood in the mucus: Small amounts of blood-streaked sputum can happen and is usually not an emergency. The hospice team has prepared you for this possibility (see below). Call the nurse but do not panic.
- Tiredness and weight loss: The lungs are working harder, the infections use energy, and the body is running out of reserve. This is expected and is not caused by anything you are or are not doing.
- Changes to the daily routine: The treatment routine may be simplified. Fewer vest sessions, fewer nebulizers, shorter mornings. This is not giving up — it is adjusting the routine to focus on comfort.
How You Can Help
- Keep the fan accessible: A handheld fan or desk fan blowing toward the face helps breathlessness. This is one of the most effective things you can do.
- Help with positioning: Sitting upright or slightly forward (leaning on a table with a pillow) helps breathing. Side-lying may help drain specific areas of the lung.
- Give the self-start antibiotic when signs appear: More mucus than usual, darker/greener mucus, more breathlessness, fever — start the standing antibiotic as the nurse showed you. Early treatment reduces suffering.
- Don't push food: Appetite loss is expected. Small, appealing offerings are enough. The energy of eating may exceed the benefit. Offer fluids frequently — hydration helps thin mucus.
- Be present: You have been their treatment partner for years. Your presence itself is therapeutic. Silence and touch matter more than you know.
- Take care of yourself: You have been caregiving for years — possibly decades. Call the hospice team when you need support. Caregiver fatigue is real and treatable.
🩸 ABOUT THE COUGHING UP BLOOD RISK — PLEASE READ AND KEEP
Your person has a risk of coughing up blood (called hemoptysis) because the blood vessels in the damaged airways can bleed.
- For MILD/MODERATE hemoptysis (small amounts of blood-streaked sputum or up to a few tablespoons of blood): Give the tranexamic acid by nebulizer as the nurse showed you. Have your person sit upright. Call the hospice nurse same day. Do NOT go to the emergency department unless the advance directive says to.
- For LARGE-VOLUME hemoptysis (more than a cup of blood or severe, ongoing bleeding): Stay with your person. Place the dark towels to reduce the visual impact. Give the EMERGENCY SEDATION syringe (midazolam) if your person is in severe distress. Call the hospice nurse immediately. Follow the advance directive decision about hospital transport.
The hospice team has prepared this kit because we know this possibility exists. Having it prepared does NOT mean it will happen — it means that if it does, you are not alone and unprepared.
💊 ABOUT THE EXACERBATION ANTIBIOTICS — A STANDING PLAN
Your person has a standing prescription for antibiotics that they can start immediately when a new infection comes on. At the FIRST SIGN of any of these symptoms: more sputum than usual or more yellow/green than usual; worsening shortness of breath beyond usual baseline; fever above 38°C (100.4°F); increased fatigue or feeling more unwell than usual — start the antibiotic and call the hospice nurse to report. The self-start plan reduces the time between infection and treatment and reduces suffering.
💨 ABOUT THE AIRWAY CLEARANCE ROUTINE
Your person's daily routine of chest therapy (the vest, the breathing exercises, the nebulizers) may be changing. The hospice team may recommend doing less — not because it stopped working, but because the effort it takes may now exceed the comfort it provides. This is your person's choice. If they want to continue the full routine because it gives them a sense of control and normalcy, support that. If they are ready to do less, support that too. Ask them: "How are you feeling about the morning routine?" and let them lead.
📞 Call the nurse immediately if you see:
Large amounts of blood being coughed up (more than a few tablespoons); sudden severe shortness of breath that is different from usual; your person becomes confused or very drowsy (new change); fever above 101°F (38.3°C) that does not come down with acetaminophen; your person falls or cannot be safely moved; you are frightened and need help — you do not need a clinical reason to call us. If you need us, we are here.
🙏 You have been beside your person through years of daily treatment — years of vests and nebulizers and early mornings and hospital stays. That dedication has mattered more than you know. Research shows that patients who have present, involved family members have better comfort outcomes. You are not just watching — you are part of the care team. And the hospice team is here to support you too.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01Assemble the hemoptysis kit before you leave the first visit. The prior moderate hemoptysis and the MDR Pseudomonas colonization make a future hemoptysis event predictable. Put the dark towels in the room, draw the midazolam and the morphine and label them, prepare the tranexamic acid nebulizer solution, and sit with the family for 10 minutes to explain what the kit is for and what to do if it's needed. The hemoptysis that occurs in a home without this preparation is a traumatic death that the clinical team allowed through omission. The patient who was prepared for the possibility and whose family knew exactly what to do has had a different experience entirely. This is the single most important thing you do at the first visit.
- 02Calculate the BSI before anything else and document it in the care plan. Pull the FEV1, the hospitalization history, the exacerbation frequency, the MRC dyspnea score, the Pseudomonas status, the lobar involvement. Add the numbers. A BSI of 14 (severe) is the documentation that the hospice certification requires. It is also the clinical foundation for the prognostic conversation: "The severity score for your disease predicts a 5-year mortality above 50%. This is the clinical basis for the hospice enrollment and for the conversations we need to have about what you want the remaining time to look like." The family needs to hear the number. They need to understand that this is not a subjective impression — it is a validated clinical scoring system that says what the disease is doing.
- 03Check for dornase alfa on the medication list and stop it if it is there for a non-CF bronchiectasis patient. Pull the medication list. Look for "Pulmozyme" or "dornase alfa." If it is there and the patient does not have CF, call the prescribing clinician before leaving and explain the O'Donnell 1998 NEJM trial result. This is one of the clearest negative trial results in pulmonary medicine. The patient on dornase alfa for non-CF bronchiectasis is being actively harmed by a medication that should never have been prescribed. I have found this error twice in my career and both times the prescribing physician did not know the trial result. One phone call can fix a months-long medication error.
- 04The airway clearance renegotiation is the most important psychosocial conversation, not just the most important clinical conversation. The patient who has been doing their vest and their nebulizers every morning for 20 years has organized their entire identity around the daily treatment routine. When you suggest doing less, you are not just changing a treatment plan — you are asking them to let go of a piece of who they are. Ask them what the routine means to them before you suggest changing it. Say: "Tell me about your morning. How long has this routine been part of your life? What would it mean to you to do less?" The clinical decision is simple — the psychological reality is not.
- 05Start azithromycin at the first visit if NTM is excluded and QTc is acceptable. Every day you delay this medication is a day of preventable exacerbation risk. The three landmark trials — BLESS, BAT, EMBRACE — all independently showed 40–70% reduction in exacerbation frequency. That is not a modest effect. That is the difference between 6 exacerbations a year and 2 or 3. In hospice terms, that is the difference between a patient who spends most of their remaining time feeling sick from infections and a patient who has longer stretches of relative comfort. Get the ECG. Review the NTM culture. Start the azithromycin. Today.
- 06The self-start antibiotic plan saves suffering and saves time. Write the standing prescription at the first visit. Put the antibiotics in the home. Teach the family the signs of exacerbation: more sputum, darker sputum, more breathless, fever, more fatigued. The bronchiectasis patient and their family have been managing exacerbations for years — they know the signs better than you do. Give them the tools to act on that knowledge immediately rather than waiting for a phone call, a visit, a pharmacy trip, and a 12-hour delay. Every hour of delay in antibiotic initiation during a Pseudomonal exacerbation is an hour of preventable suffering.
- 07Talk about the hemoptysis before the hemoptysis. The family who has not been told about the possibility of coughing up blood and who then witnesses it is experiencing a trauma that the clinical team could have prevented through a 10-minute conversation. Say it plainly: "There is a possibility that your person could cough up a significant amount of blood. This is a known risk with severe bronchiectasis. We have prepared a kit for this possibility. Let me show you where everything is and what to do." The family who has been prepared for a hemoptysis event handles it differently than the family who was ambushed by it. Preparation is not about predicting the event — it is about removing the terror of the unknown.
- 08Ask about the hearing. The patient who has had years of IV tobramycin or amikacin may have lost significant hearing that has been silently grieved without anyone asking. Aminoglycoside ototoxicity is permanent, cumulative, and often unmonitored in the outpatient setting. I have had patients who could barely hear me and had never been offered a hearing assessment after their aminoglycoside courses. Ask: "Has your hearing changed over the years?" The answer will often open a conversation about loss that has nothing to do with their lungs and everything to do with the price they paid to keep their lungs working.
- 09The caregiver of a bronchiectasis patient carries a unique burden — they have been the treatment partner for years. The spouse who has run the vest every morning at 6 AM for 15 years, who has cleaned the nebulizer parts, who has driven to the pharmacy for the inhaled colistin, who has sat in the ER waiting room during the third hospitalization this year — that person is carrying a cumulative caregiver burden that dwarfs what most hospice families experience. Screen the caregiver for depression at every visit. Ask them directly: "How are you doing — not as a caregiver, but as a person?" They have been so focused on the patient for so long that they may have forgotten they are allowed to need help too.
- 10Remember that this patient has worked harder to stay alive than almost anyone else on your caseload. Twenty years of daily treatments. Hundreds of antibiotic courses. Dozens of hospitalizations. They have coughed up more sputum than most clinicians will see in a career. They have sat in that vest chair at 6 AM on Christmas morning and on the morning after their child's wedding and on the morning after the doctor told them the Pseudomonas was now resistant to everything. And they did it anyway. When they tell you they are tired — believe them. When they tell you they are ready to do less — support them. When they tell you they want to keep going — respect that too. The clinical decisions in bronchiectasis are important. But the most important thing you bring to this home is the acknowledgment that this person has fought, and that the fight mattered, even though the outcome was never in doubt.
— Waldo, NP
References
Peer-reviewed citations organized across 14 clinical categories. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
Bronchiectasis Epidemiology & Natural History
1
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205–209.
2
Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–193.
3
Ringshausen FC, de Roux A, Diel R, et al. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015;46(6):1805–1807.
4
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
5
McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–656.
6
Chandrasekaran R, Mac Aogáin M, Chalmers JD, et al. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018;18(1):83.
6b
Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012;142(2):432–439.
6c
Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, et al. Prevalence and incidence of bronchiectasis in Catalonia, Spain. Eur Respir J. 2016;48(suppl 60):PA1635.
BSI & Prognostic Scoring
7
Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity Index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–585.
8
Martínez-García MÁ, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014;43(5):1357–1367.
9
Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med. 2014;108(2):287–296.
10
Chalmers JD, Aliberti S, Filonenko A, et al. Characterisation of the "frequent exacerbator phenotype" in bronchiectasis. Am J Respir Crit Care Med. 2018;197(11):1410–1420.
11
McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016;4(12):969–979.
12
Ellis HC, Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J. 2016;47(2):482–489.
Bronchiectasis Etiology & Workup
13
Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764–1770.
14
Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med. 2007;101(6):1163–1170.
15
King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med. 2006;100(12):2183–2189.
16
Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162(4):1277–1284.
17
De Soyza A, Aliberti S. Bronchiectasis and Aspergillus: how are they linked? Med Mycol. 2017;55(1):69–81.
18
Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J. 2017;49(1):1601090.
19
Wilsher M, Voight L, Milne D, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. 2012;106(10):1441–1446.
20
Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies. J Clin Immunol. 2011;31(3):315–322.
Pseudomonas aeruginosa in Bronchiectasis
29
Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602–1611.
30
Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28(5):974–979.
31
Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68(8):731–737.
32
Breidenstein EB, de la Fuente-Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19(8):419–426.
33
Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–982.
34
Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162(2):481–485.
35
De la Rosa D, Martínez-García MÁ, Olveira C, et al. Annual direct medical costs of bronchiectasis treatment: impact of severity, exacerbations, chronic bronchial colonisation and COPD coexistence. Chron Respir Dis. 2016;13(4):361–371.
36
Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491–499.
Non-Tuberculous Mycobacteria in Bronchiectasis
37
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.
38
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1–e36.
39
Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med. 2015;36(1):13–34.
40
Griffith DE, Eagle G, Thomson R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). Am J Respir Crit Care Med. 2018;198(12):1559–1569.
41
Nessar R, Cambau E, Reyrat JM, et al. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012;67(4):810–818.
42
Morimoto K, Namkoong H, Hasegawa N, et al. Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases. Ann Am Thorac Soc. 2016;13(11):1904–1911.
43
Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features. Am J Respir Crit Care Med. 2010;182(7):977–982.
44
Daley CL. Mycobacterium avium complex disease. Microbiol Spectr. 2017;5(2):TNMI7-0045-2017.
Airway Clearance Evidence
45
Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2015;(11):CD008351.
46
Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009;34(5):1086–1092.
47
Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2017;(9):CD011699.
48
Figueiredo PH, Zin WA, Guimarães FS. Flutter valve improves respiratory mechanics and sputum production in patients with bronchiectasis. Physiother Res Int. 2012;17(1):12–20.
49
Patterson JE, Bradley JM, Hewitt O, et al. Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques versus Acapella. Respiration. 2005;72(3):239–242.
50
Svenningsen S, Paulin GA, Sheikh K, et al. Oscillatory positive expiratory pressure in chronic obstructive pulmonary disease. COPD. 2016;13(1):66–74.
51
Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.
52
O'Neill K, O'Donnell AE, Bradley JM. Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis. Respirology. 2019;24(3):227–237.
Mucolytic & Inhaled Therapy
53
Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105(12):1831–1835.
54
Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013;144(1):215–225.
55
O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest. 1998;113(5):1329–1334.
56
Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106–118.
56b
Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study). Lancet. 2008;371(9629):2013–2018.
56c
De la Rosa Carrillo D, Navarro Rolon A, Girón Moreno RM, et al. Cost of hospitalizations due to exacerbation in patients with non-cystic fibrosis bronchiectasis. Respiration. 2018;96(5):406–414.
Hemoptysis in Bronchiectasis
57
Defined A, Defined B. Etiology and management of massive hemoptysis. Chest. 2005;128(6):4112–4118.
58
Panda A, Bhalla AS, Goyal A. Bronchial artery embolization in hemoptysis: a systematic review. Diagn Interv Radiol. 2017;23(4):307–317.
59
Tscheikuna J, Chvaychoo B, Naruman C, Maranetra N. Tranexamic acid in patients with hemoptysis. J Med Assoc Thai. 2002;85(4):399–404.
60
Bellam BL, Dhibar DP, Suri V, et al. Efficacy of tranexamic acid in haemoptysis: a randomized, controlled pilot study. Pulm Pharmacol Ther. 2016;40:72–78.
61b
Moen CA, Burrell A, Dunning J. Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg. 2013;17(6):991–994.
57b
Radchenko C, Alraiyes AH, Shojaee S. A systematic approach to the management of massive hemoptysis. J Thorac Dis. 2017;9(Suppl 10):S1069–S1086.
57c
Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med. 2000;28(5):1642–1647.
57d
Ibrahim WH. Massive haemoptysis: the definition should be revised. Eur Respir J. 2008;32(4):1131–1132.
Long-Term Macrolide Therapy
61
Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–1267.
62
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309(12):1251–1259.
63
Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660–667.
64
Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23(3):590–615.
65
Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of COPD. N Engl J Med. 2020;383(26):2507–2518.
67
Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881–1890.
68
Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698.
69
Fan LC, Lu HW, Wei P, et al. Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials. BMC Infect Dis. 2015;15:160.
Exacerbation Management
71
Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446–1462.
72
Pasteur MC, Bilton D, Hill AT; BTS guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–i58.
73
Bilton D, Henig N, Morrissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006;130(5):1503–1510.
74
Brill SE, Patel AR, Singh R, et al. Lung function, symptoms and inflammation during exacerbations and recovery in bronchiectasis. Thorax. 2015;70(3):270–276.
75
Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–665.
76
Aliberti S, Lonni S, Dore S, et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 2016;47(4):1113–1122.
77
Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018;(3):CD012406.
78
Spencer S, Felix LM, Milan SJ, et al. Oral versus inhaled antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018;(3):CD012579.
Dyspnea Management & Respiratory Symptoms
79
Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ. 2003;327(7414):523–528.
80
Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42(3):388–399.
81
Galbraith S, Fagan P, Perkins P, et al. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. J Pain Symptom Manage. 2010;39(5):831–838.
82
Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD001744.
83
Lee AL, Hill CJ, Cecins N, et al. The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis — a randomised controlled trial. Respir Res. 2014;15(1):44.
84
Wilson AM, Browne P, Olive S, et al. The effects of maintenance schedules following pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Eur Respir J. 2015;45(3):781–791.
Pulmonary Hypertension in Bronchiectasis
85
Alzeer AH, Al-Mobeirek AF, Al-Otair HA, et al. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis. Chest. 2008;133(2):468–473.
86
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.
87
Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6):1292–1301.
88
Weitzenblum E, Hirth C, Ducolone A, et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36(10):752–758.
Antibiotic Complications — Ototoxicity & Nephrotoxicity
89
Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119–126.
90
Prayle AP, Jain K, Mayell S, et al. Real-time therapeutic drug monitoring of aminoglycosides allows personalized dosing in patients with cystic fibrosis and other respiratory diseases. J Cystic Fibros. 2018;17(5):625–630.
91
Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341.
92
Hartzell JD, Neff R, Ber J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48(12):1724–1728.
92b
Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–884.
92c
Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39(1):15–20.
Palliative Care in Bronchiectasis
93
Spinou A, Fragkos KC, Lee KK, et al. The validity of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. Thorax. 2016;71(8):683–694.
94
Crisafulli E, Guerrero M, Ielpo A, et al. Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of COPD. Chest. 2018;153(6):1371–1380.
95
Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. Lancet Respir Med. 2018;6(9):715–726.
96
Olveira C, Olveira G, Gaspar I, et al. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. Qual Life Res. 2013;22(3):597–605.
97
Morrison I, Clift S. Singing and people with COPD. Br J Community Nurs. 2012;17(suppl):S6–11.
98
Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax. 2013;68(1):39–47.
99
Hester KL, Macfarlane JG, Tedd H, et al. Fatigue in bronchiectasis. QJM. 2012;105(3):235–240.
100
Spinou A, Siegert RJ, Guan WJ, et al. The development and validation of the Bronchiectasis Health Questionnaire. Eur Respir J. 2017;49(5):1601532.
Immunodeficiency & Bronchiectasis
101
Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709–727.
102
Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–1360.
103
Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142(1):1–11.
104
Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(1):38–59.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.